<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05616962</url>
  </required_header>
  <id_info>
    <org_study_id>PLP-01</org_study_id>
    <nct_id>NCT05616962</nct_id>
  </id_info>
  <brief_title>Collected Data of Medical Food, Vasculera or Diosmiplex, in Clinic Patients 20 to 70 Years Old Diagnosed With Lipedema</brief_title>
  <official_title>Vasculera in Participants With Lipedema an Exploratory Controlled Case Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Primus Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Northeastern University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Primus Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to gain preliminary information via a uniform protocol regarding the&#xD;
      clinical effects of Vasculera in patients with lipedema and the possible role of the&#xD;
      glycocalyx as a physiological target for Vasculera activity. It is anticipated that the&#xD;
      results of this case study will inform the development of a formal randomized, double-blind,&#xD;
      placebo controlled trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this type of clinical trial is to compare the measurement of participants legs&#xD;
      before treatment and after using the treatment for approximately 3 months in clinic patients&#xD;
      20 to 70 years old with lipedema. The main questions it aims to answer are: does the leg&#xD;
      circumference decrease and does the participants' overall wellbeing improve? Participants&#xD;
      will:&#xD;
&#xD;
        -  Have physical examinations and measurements at baseline and 3 month visit&#xD;
&#xD;
        -  Complete wellbeing self-assessments at baseline and 3 month visit&#xD;
&#xD;
        -  Have blood drawn for chemical markers at baseline and 3 month visit&#xD;
&#xD;
        -  Complete four visits total&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 20, 2019</start_date>
  <completion_date type="Actual">September 23, 2019</completion_date>
  <primary_completion_date type="Actual">September 23, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>three (3) month open-label case study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Leg Circumference</measure>
    <time_frame>Baseline to month 3 visit</time_frame>
    <description>Percentage of change of leg circumference at 2 and 12 inches above the malliol bilaterally</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Lipedema</condition>
  <arm_group>
    <arm_group_label>Vasculera</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Vasculera 630 milligrams, two times per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Diosmiplex</intervention_name>
    <description>diosmin glycoside in combination with alkaline granules known as alka4-complex</description>
    <arm_group_label>Vasculera</arm_group_label>
    <other_name>Vasculera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. established diagnosis of lipedema for at least one (1) year&#xD;
&#xD;
          2. women, ages 20 to 70 years&#xD;
&#xD;
          3. score of at least 4 out of 10 on self-assessment on a 0-10 scale (10=worst) for&#xD;
             overall sense of well being&#xD;
&#xD;
          4. be willing to stop compression therapy for one week prior to each visit&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. other forms of leg enlargement, including lymphedema&#xD;
&#xD;
          2. any primary systemic vasculopathy&#xD;
&#xD;
          3. history of exposure to Vasculera or other diosmin containing medication within one (1)&#xD;
             year of the screening visit&#xD;
&#xD;
          4. concomitant use of warfarin, platelet inhibitors, factor Xa inhibitors or any&#xD;
             medication intended to reduce blood coagulability&#xD;
&#xD;
          5. concomitant use of diclofenac, metronidazole or chlorzoxazone&#xD;
&#xD;
          6. uncontrolled hypertension (BP&gt;170/110), unstable cardiac disease, active skin&#xD;
             ulceration&#xD;
&#xD;
          7. any other disease or condition that, in the opinion of the investigator, might put the&#xD;
&#xD;
          8. subject at risk by participation in this study OR confound evaluation of response to&#xD;
             Vasculera&#xD;
&#xD;
          9. history of substance abuse within one (1) year of the screening visit or of current&#xD;
             alcohol consumption more than one (1) unit daily. For purposes of this study, a unit&#xD;
             of alcohol will be considered to be 12 oz of beer, 6 oz of wine or 1 oz of hard&#xD;
             spirits.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Levy, MD</last_name>
    <role>Study Director</role>
    <affiliation>Primus Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Primus Pharmaceuticals</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2022</verification_date>
  <study_first_submitted>November 7, 2022</study_first_submitted>
  <study_first_submitted_qc>November 7, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2022</study_first_posted>
  <last_update_submitted>November 7, 2022</last_update_submitted>
  <last_update_submitted_qc>November 7, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lipedema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Article written by investigator Response to all queries</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>120 days from NCT assignment</ipd_time_frame>
    <ipd_access_criteria>Access will be given when requested by qualified researchers engaging in independent scientific research, and will be provided following review and approval of a research proposal.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

